What is the target of osimertinib/osimertinib?

Osimertinib/Osimertinib (Osimertinib) is a targeted drug for non-small cell lung cancer (NSCLC). Its main target is the epidermal growth factor receptor (EGFR) in tumor cells. EGFR is a receptor tyrosine kinase located on the cell membrane. It is involved in regulating important physiological processes such as cell growth, proliferation and survival. EGFROveractivation or mutation can lead to the development and progression of cancer, especially in NSCLC.

Osimertinib/The targets of Osimertinib mainly include the following aspects:

1.EGFRactivity inhibition:Osimertinib/Osimertinib exerts its anti-tumor effect by specifically inhibiting the activity of EGFR. Compared with the first and second generation EGFR inhibitors, osimertinib has a more significant effect on EGFR mutations and EGFR activation, and has less impact on normal cells.

2.EGFRmutation suppression:Osimertinib/Osimertinib specifically targets EGFR gene mutations, such as EGFRsensitive mutations (such as Del19 and L858R) and EGFR T790M mutation. These mutations are the most common EGFR mutations in NSCLC and are closely related to tumor occurrence, growth and metastasis.

3.EGFR T790Mmutation suppression: Osimertinib/Osimertinib has high selectivity, specifically targeting the EGFR T790M mutation, which is a common drug-resistant mutation. By inhibiting the EGFR T790M mutation, osimertinib can overcome the resistance of other EGFR inhibitors, thereby prolonging patient survival and improving treatment efficacy.

In general, Osimertinib/Osimertinib interferes with the growth and spread of tumor cells by specifically inhibiting the EGFR signaling pathway, thereby exerting its anti-tumor effect. Its main targets are EGFR and its mutant forms, especially the targeting effect on EGFR T790M mutation, making it one of the important drugs in the treatment of NSCLC. Although Osimertinib/Osimertinib has a significant therapeutic effect, drug resistance may still occur during treatment, so close monitoring and individualized treatment strategies are required.